1,1,1,2,2-Pentafluoro-3,3-dimethylbutane | 67498-75-3

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 1,1,1,2,2-Pentafluoro-3,3-dimethylbutane
• CAS: 67498-75-3
• 化学式: C₆H₉F₅
• 分子量: 176.13
• InChiKey: OSFWBHRTAVJAME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Heterocyclic Compounds and Methods of Use
  申请人：Medivation Technologies, Inc.

  公开号：US20180028518A1

  公开（公告）日：2018-02-01

  This disclosure provides compounds and methods of using those compounds to treat liver fibrosis, including liver fibrosis which is a precursor to, is concurrent with, is associated with, or is secondary to nonalcoholic steatohepatitis (NASH); elevated cholesterol levels, and insulin resistance.

  本公开提供了化合物和使用这些化合物治疗肝纤维化的方法，包括作为非酒精性脂肪性肝炎（NASH）的前体、与NASH同时发生、与NASH相关或次生于NASH的肝纤维化的治疗方法；高胆固醇水平和胰岛素抵抗。
• 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF
  申请人：Bayer Aktiengesellschaft

  公开号：US20190263805A1

  公开（公告）日：2019-08-29

  The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.

  本申请涉及新颖的7-取代的1-芳基喹啉并吡啶-3-羧酰胺，其制备方法，其单独或组合使用，用于治疗和/或预防疾病，以及用于生产药物以治疗和/或预防疾病，特别是用于治疗和/或预防心血管疾病和/或肾脏疾病。
• [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS
  申请人：FOGHORN THERAPEUTICS INC

  公开号：WO2020160198A1

  公开（公告）日：2020-08-06

  The present invention relates to compositions and methods for the treatment of BAF-related disorders, such as cancers and viral infections.

  本发明涉及用于治疗与BAF相关的疾病，如癌症和病毒感染的组合物和方法。
• Atropisomers and Methods of Altering Enantiomeric Excess
  申请人：Florida State University Research Foundation, Inc.

  公开号：US20180179120A1

  公开（公告）日：2018-06-28

  Provided herein are methods of altering enantiomeric excess. The methods may include irradiating an atropisomer that includes at least one chiral substituent to alter the enantiomeric excess of the atropisomer. The at least one chiral substituent may be removed following irradiation.

  本文提供了改变对映体过量的方法。这些方法可能包括照射至少含有一个手性取代基的异构体，以改变该异构体的对映体过量。照射后，可以去除至少一个手性取代基。
• Heterocyclic compounds and methods of use
  申请人：Medivation Technologies LLC

  公开号：US10183015B2

  公开（公告）日：2019-01-22

  This disclosure provides compounds and methods of using those compounds to treat liver fibrosis, including liver fibrosis which is a precursor to, is concurrent with, is associated with, or is secondary to nonalcoholic steatohepatitis (NASH); elevated cholesterol levels, and insulin resistance.

  本公开提供了化合物和使用这些化合物治疗肝纤维化的方法，包括作为非酒精性脂肪性肝炎（NASH）前兆、与之并发、相关或继发的肝纤维化；胆固醇水平升高和胰岛素抵抗。